Pediatric Cancer

Approximately one-fourth of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping their tumors in the screening protocol of the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial.
“Considering the frequency of both pediatric cancer survivorship and of late toxicities related to treatment, childhood cancer is often the cancer diagnosis that lasts a lifetime.”

Results 1 - 2 of 2